Susan Blair appointed as Head of Boehringer Ingelheim Animal Health in Canada

Blair joined Boehringer Ingelheim Canada in 2003 and was most recently Executive Director, Animal Health, a position she held since 2010.

Blair holds a Degree in Agriculture from the University of Saskatchewan. She began her career in grain and cattle production and brought that experience to the pharmaceutical industry where she has worked across species including poultry, swine, cattle and companion animals.  

This appointment follows the transactional closing of the exchange of Sanofi’s animal health business (Merial) and Boehringer Ingelheim’s consumer healthcare (CHC) business on January 1, 2017. The combined Boehringer Ingelheim Animal Health Business unites the strengths of two leading players to create the second largest animal health business in the world.

In leading the combined business, Susan replaces Bill Lopez who has been serving as Country Manager for Merial in Canada.

Joachim Hasenmaier, Head of the Boehringer Ingelheim Animal Health Business Unit, said: “I’m pleased to appoint Susan Blair to the role of Head of Animal Health in Canada. With her extensive experience and expertise, Susan will guide the integration in Canada and help us move closer to achieving our goals. I would like to take this opportunity to thank Bill Lopez for his hard work and contribution to Merial.”

Blair is delighted to take on her new role at such an exciting time for the Boehringer Ingelheim Animal Health business and for the industry as a whole.

“We have a strong team here in Canada and I am confident that as a combined business we will be able to do even more to improve human and animal health,” she said.  

About Boehringer Ingelheim Animal Health

In January 2017, Merial became part of the Boehringer Ingelheim group. As the second largest animal health business in the world, Boehringer Ingelheim is committed to making the industry even better at improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries.  For more information about Boehringer Ingelheim Animal Health, click here.

About Boehringer Ingelheim (Canada) Ltd.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of its net sales.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

For further information or to arrange an interview with Susan Blair:

Merry Garbutt
Corporate Communications
Boehringer Ingelheim (Canada) Ltd.
Email: merry.garbutt@boehringer-ingelheim.com
Phone: (905) 631-4531